BENZONATATE | A040597 | ZYDUS PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consultant Services, Inc. FDA-2009-P-0190 · 6 docket documents Lachman Consultant Services, Inc. filed this citizen petition on behalf of a client pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Benzonatate Capsules at 125 mg and 175 mg dosage strengths suitable for consideration in an abbreviated new | Other | 2009-04-21 | Denied | Lachman Consultant Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1046
per ea
Lowest NADAC/Unit
$0.0708
per ea
Brand NDCs
0
Generic NDCs
5
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68382009101BENZONATATE 200 MG CAPSULE | $0.1046 | EA | Generic | — | 2026-06-17 |
| 00904656460BENZONATATE 100 MG CAPSULE | $0.0708 | EA | Generic | — | 2026-06-17 |
| 68382024701BENZONATATE 100 MG CAPSULE | $0.0708 | EA | Generic | — | 2026-06-17 |
| 68382024705BENZONATATE 100 MG CAPSULE | $0.0708 | EA | Generic | — | 2026-06-17 |
| 68084021401BENZONATATE 100 MG CAPSULE | $0.0708 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.